Chris Anzalone, Arrowhead CEO
Arrowhead, Takeda liver drug headed to PhIII despite placebo response's dent on stock
Arrowhead Pharmaceuticals reported Monday that its Takeda-partnered program reduced liver scarring and mutant protein levels in patients with alpha-1 antitrypsin deficiency, a rare liver disease. However, a better-than-expected placebo performance sent shares of Arrowhead $ARWR down more than 20%.
The Phase II SEQUOIA study showed the pair’s RNAi drug candidate fazirsiran reduced markers of AATD, a condition in which the body does not produce enough AAT, a protein made in the liver to protect the lungs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
